InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files 14th Patent Application, Announces New Board Member
August 17, 2021

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files 14th Patent Application, Announces New Board Member

Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed a nonprovisional patent application in support of its ongoing drug candidate programs. The company noted that it had completed a favorable international search report regarding its May 2021 Patent Cooperation Treaty (“PCT”) application; as a result, it filed the U.S. nonprovisional application claiming priority to the May 2021 PCT application. The company noted that the International Patent Searching authority had written an opinion supporting novelty, inventive steps and industrial applicability to multiple claims within Cybin’s patent filing, including claims to compositions and methods that support elements of the company’s preclinical and research programs. In addition Cybin shareholders elected a new member to its board of directors during the company’s Aug. 6, 2021, annual and special meeting of shareholders. Theresa Firestone, a senior healthcare executive with an impressive background in retail, pharmaceutical, health and wellness, government and global restructuring, will be Cybin’s newest board member. The company also noted the results for other items voted on during the meeting, which had 53 shareholders in attendance in person or by proxy. Regarding the patent application, Cybin CEO Doug Drysdale stated the following in the press release: “Cybin’s portfolio now consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies, 4 active drug programs targeting major depressive disorder, alcohol use disorder, anxiety and therapy resistant psychiatric disorders. We continue to progress our IP portfolio across novel molecules, delivery mechanisms, processes and protocols as we continue to find new and novel discoveries through our preclinical findings thus expanding and strengthening IP.”

To view the full press releases, visit https://ibn.fm/Apqzb and https://ibn.fm/f0Uyx

About Cybin Inc.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).